Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Resveratrol primed adipose stem cell-derived exosomes alleviate intestinal ischemia reperfusion injury by regulating macrophage polarization.

Ye K., Peng QF., Zhang ZG., Li X., Xue HB., Guo H.

Animal Study on Chronic Inflammation, published in Int Immunopharmacol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Int Immunopharmacol (2025)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
40907329
DOI
10.1016/j.intimp.2025.115481

Abstract (original English)

Intestinal ischemia/reperfusion injury (IRI) is a severe clinical condition associated with high morbidity and mortality. Despite advances in understanding the pathophysiology of IRI, effective therapeutic strategies remain limited. Adipose stem cell (ADSC)-derived exosomes (Exo) have been proven to be appropriate candidates for IRI through the anti-inflammatory effects. In this study, we investigated whether resveratrol (RSV)-primed ADSC-derived exosomes (RSV-primed Exo) could exert superior effects on alleviating intestinal IRI, and attempted to elucidate the underlying mechanism. For the evaluation of the therapeutic effect of the RSV-primed Exo on intestinal IRI, in vitro and in vivo studies were performed. IRI model was established in male C57BL/6 mice by clamping the superior mesenteric artery for 45 min followed by reperfusion. Histopathological analysis, intestinal barrier, the proportion of T cells, and macrophage polarization were investigated. RSV-primed Exo mediated immunosuppressive activity was investigated by bone marrow-derived macrophages (BMDM) co-culture assay in vitro. Flow cytometry determined macrophage polarization. ELISA assays detected the function of macrophages. Furthermore, the role of the NF-κB pathway in RSV-primed Exo induced macrophage polarization was also elucidated. In vivo modeling in intestinal IRI showed that RSV pretreatment enhanced the t

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsExosomesResveratrolReperfusion InjuryMaleMice, Inbred C57BLMacrophagesMiceAdipose TissueIntestines

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research